Cagrilintide, a long-acting amylin analog, has now completed pivotal Phase 3 trials as part of the CagriSema combination with semaglutide, delivering over 20% mean body weight loss and prompting a New Drug Application to the FDA.
Cagrilintide is a synthetic, fatty-acid-acylated analog of amylin � a satiety hormone co-secreted with insulin by pancreatic beta cells. Novo Nordisk engineered the molecule with structural modifications that extend its half-life to approximately one week, enabling once-weekly subcutaneous dosing. Because amylin signals via different receptors than GLP-1, pairing cagrilintide with semaglutide creates a complementary, additive mechanism: GLP-1 agonism suppresses appetite through the gut-brain axis, while amylin receptor activation further slows gastric emptying and reduces caloric intake through a distinct signaling pathway.
The Phase 3 REDEFINE 1 trial, published in the New England Journal of Medicine, showed that CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg, once weekly) produced a mean body weight reduction of 22.7% at week 68 in adults with overweight or obesity without type 2 diabetes. Sixty percent of participants on CagriSema achieved at least 20% weight loss � a threshold rarely crossed by any single pharmacological agent. Over half of CagriSema-treated participants reached a non-obese BMI below 30. The companion REDEFINE 2 trial demonstrated a 13.7�15.7% mean weight reduction in patients with obesity and type 2 diabetes, along with dramatic glycemic improvements: 73.5% of CagriSema participants reached an HbA1c of 6.5% or lower, compared to just 15.9% on placebo.
Despite those strong numbers, a February 2026 readout from the head-to-head REDEFINE 4 trial showed CagriSema failing to achieve non-inferiority against tirzepatide 15 mg over 84 weeks, a reminder of how competitive the obesity pharmacology space has become. Nonetheless, Novo Nordisk filed an NDA with the FDA on December 18, 2025, positioning CagriSema as the first-ever injectable combination of a GLP-1 receptor agonist and an amylin analog for chronic weight management. An FDA decision is expected around October�November 2026 under the standard 10-month review timeline.
For clinicians and patients tracking the obesity drug pipeline, cagrilintide represents an important mechanistic diversification beyond the GLP-1/GIP axis. Its amylin-based action adds a complementary satiety signal and offers a rationale for combination strategies even as newer triple agonists such as retatrutide push efficacy benchmarks higher. Whether CagriSema earns FDA approval in late 2026 will depend on how regulators weigh the REDEFINE 1 and 2 data alongside the competitive landscape set by tirzepatide.
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.